Genetic Immunity Reports Positive Results of HIV Immune Therapy
Posted on: Tuesday, 12 February 2008, 09:01 CST
Genetic Immunity has announced positive clinical safety and immunogenicity data on its DermaVir Patch, a topically administered HIV immune therapy.
Genetic Immunity studied nine HIV infected individuals on fully suppressive antiretroviral therapy who were treated a single time with either 0.1, 0.4 or 0.8mg of multiple HIV antigens encoding plasmid DNA, the active substance in DermaVir Patch. The same antiretroviral drug regimen was continued during the one-year follow-up.
The DermaVir Patch treatment resulted in significant induction of PHPC counts in all nine patients in the study. Importantly, these precursor T cell responses were long lasting; 10-100 fold increased PHPC counts over baseline were detected during the one year follow up. Safety was assessed with standard clinical and laboratory evaluations, and dermatological analysis of skin reaction. DermaVir Patch continued to show a lack of dose limiting toxicities. Through multiple studies, the only side effect seen so far has been limited to transient erythema (redness of the skin).
Julianna Lisziewicz, co-founder and CEO of Genetic Immunity, said: "The Genetic Immunity team is encouraged by this data, which suggests that the DermaVir Patch is on its way to becoming the first immune therapy for HIV-infected individuals."
Source: Datamonitor
Related Articles
- SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma to Provide Next-Generation Hair Loss Treatment Genetic Testing
- Genetic Immunity(R) Announces First Patient Dosed In Phase II Trial With DermaVir Patch For HIV Disease
- Genetic Immunity to Present at 2008 BIO International Convention
- Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
- Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
- Genetic Immunity Closes $2 Million Dollar Bridge Financing
- Mirus Bio Announces Efficient New Genetic Immunization Method to Produce Antibodies
- CytoDyn Selects Quest Clinical Research for Next Trial of HIV/AIDS Immune Therapy
- Data Indicate That Whole-Inactivated HIV-1 Immunogen Induces HIV-Specific Immune Responses in HIV-Infected, HAART-Naive Patients; Final Data From IMNR.OB's Italian Study Presented in Poster at CROI Annual Meeting
 |
 |
User Comments (0)
RSS Feeds